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Abstract
The early steps of retrovirus replication leading up to provirus establishment are highly dependent on cellular processes and
represent a time when the virus is particularly vulnerable to antivirals and host defense mechanisms. However, the roles
played by cellular factors are only partially understood. To identify cellular processes that participate in these critical steps,
we employed a high volume screening of insertionally mutagenized somatic cells using a murine leukemia virus (MLV)
vector. This approach identified a role for 39-phosphoadenosine 59-phosphosulfate synthase 1 (PAPSS1), one of two
enzymes that synthesize PAPS, the high energy sulfate donor used in all sulfonation reactions catalyzed by cellular
sulfotransferases. The role of the cellular sulfonation pathway was confirmed using chemical inhibitors of PAPS synthases
and cellular sulfotransferases. The requirement for sulfonation was mapped to a stage during or shortly after MLV provirus
establishment and influenced subsequent gene expression from the viral long terminal repeat (LTR) promoter. Infection of
cells by an HIV vector was also shown to be highly dependent on the cellular sulfonation pathway. These studies have
uncovered a heretofore unknown regulatory step of retroviral replication, have defined a new biological function for
sulfonation in nuclear gene expression, and provide a potentially valuable new target for HIV/AIDS therapy.
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Introduction
The Retroviridae are a large viral family that includes the human
pathogens Human Immunodeficiency Viruses 1 and 2 (HIV-1 and
HIV-2), the causative agents of acquired immune deficiency
syndrome (AIDS). Due to their small coding capacity and
requirement for integration into the host cell genome, retroviruses
are heavily dependent upon host cell machinery for efficient
replication. The retroviral lifecycle can be divided into two distinct
phases. The early stage consist of virus binding to a cellular receptor,
fusion of viral and cellular membranes leading to delivery of the viral
core into the cytoplasm, reverse transcription of the positive strand
RNA genome to generate a dsDNA product, translocation of viral
nucleoprotein complexes to the nucleus, and provirus establishment
through integration of the viral DNA into the host cell genome. The
late stage consists of transcription of the viral genome by host RNA
pol II, RNA processing and export to the cytoplasm, translation of
viral proteins, viral assembly, egress and maturation.
While progress hasbeen made on theidentification ofmany ofthe
cellular proteins involved in the late stage of the retroviral lifecycle,
particularly in transcription, RNA processing and egress, less is
known about the contribution of cellular factors to the early stage of
the retroviral lifecycle. In particular, the contribution of cellular
factors to steps subsequent to virus:cell membrane fusion and that
lead to proviral DNA establishment are only partially understood
[1]. A number of cellular factors that facilitate early steps in infection
have been identified,although in some cases the roles of thesefactors
are controversial. These factors include the actin cytoskelton and
microtubule network [2–7], LAP-2a, barrier-to-autointegration
factor (BAF), and emerin [8–15], SUMOylation factors [16],
importins [17–19], tRNAs [20] and LEDGF [21–28]. Although a
recent genome-wide siRNA screen uncovered a number of cellular
genes that contribute to various stages of HIV infection, it was
notable that only a few additional factors were described that are
associated with either viral DNA synthesis or integration [17]. It
therefore seems likely that other, as yet unidentified, cellular factors
participate in early retroviral replication.
To identify other cellular factors that are involved, we have
employed a somatic cell mutagenesis-based approach. This study
led to the identification of the 39-phosphoadenosine 59-phospho-
sulfate synthase 1 (PAPSS1) gene as playing an important role in
retroviral replication. PAPSS1 and PAPSS2 are homologous
enzymes that synthesize 39-phosphoadenosine 59-phosphosulfate
(PAPS), the high energy sulfate donor used in all known sulfonation
reactions catalyzed by cellular sulfotransferases [29]. Golgi
sulfotransferases catalyze the sulfonation of lipids, of carbohydrates,
and of tyrosines in proteins [29–33]. Cytoplasmic sulfotransferases
lead to the sulfonation of a wide variety of peptides, hormones and
xenobiotics [29,34]. The data described in this report reveal a novel
role for the cellular sulfonation pathway in retroviral replication
during provirus establishment, one that modulates the subsequent
transcriptional competency of the provirus.
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Plasmids and viral vectors
A schematic of the proviral forms of the MLV constructs used in
this paper is provided in Figure S1. The viral genome plasmids
pMMP-nls-LacZ, pCMMP-eGFP and pCMMP-IRES-GFP,
pCMMP-CD4-eGFP, pHIV-TVA800-hcRED, pRET and the
ASLV-A genome plasmid RCASBP(A)-AP have been previously
described [35–37]. The MLV vectors pLEGFP (Clontech, Palo
Alto, CA) and pQCLIN (Clontech, Palo Alto, CA) as well as the
HIV-1 self inactivating (SIN) pLenti6/V5-GW/lacZ (Invitrogen,
Carlsbad, CA) were obtained commercially. The HIV-1 vector
pNL4-3.Luc.R-E- [38] was obtained from the NIH AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH (deposited by Dr. Nathaniel Landau).
To construct the MLV vector pCMMP-CD4 (expressing human
CD4 from the viral LTR), the previously described pCMMP-CD4-
eGFP vector [39] was digested with PmlI and HpaI to remove the
IRES-eGFP cassette and then the plasmid was re-ligated. The MLV
vector pCMMP-HcRED (encoding the red fluorescent protein
HcRED from the viral LTR) was generated by removing the
multiple cloning site and IRES from pCMMP-IRES-GFP by AgeI/
HpaI digestion and inserting an AgeI/StuI fragment containing the
HcRED coding sequence from pHcRED1 (Clontech, Palo Alto,
CA). The MLV vector pCMMP-SEAP-IRES-GFP (encoding SEAP
and GFP) was generated by inserting the SEAP gene from pSEAP-
control(Clontech,PaloAlto,CA)upstreamoftheIRESinpCMMP-
IRES-GFP. HIV-1 vectors for stable expression of PAPS synthases
or control cDNAs were generated by PCR amplification of coding
sequence (PAPSS1: IMAGE#3869484, PAPSS2: IM-
AGE#2988345, control cDNA ZNF639:IMAGE#4794621) from
commercially available cDNAs (Open Biosystems) and cloning into
MluI/EcoRV digested pLenti6/V5-GW/lacZ.
Cell culture and virus production
Chinese hamster ovary cells (CHO-K1, ATCC CCL-61) were
cultured in F-12 media supplemented with 10% bovine calf serum
(BCS) (Invitrogen, Carlsbad, CA). Human embryonic Kidney
293T cells (ATCC CRL-11268) were cultured in DMEM
supplemented with 10% fetal calf serum (FCS) (Hyclone, Logan,
UT). Chicken DF-1 cells (ATCC CRL-12203) were cultured in
DMEM supplemented with 10% FCS. Jurkat cells (ATCC TIB-
152) were cultured in RPMI-1640 supplemented with 10% FCS.
CHO cells expressing the receptor for ASLV (TVA-800) were
generated as previously described [39] by infection with HIV-1-
TVA800-hcRED[VSV-G] at an approximate moi of 0.5 hcRED
transducing units for 2 hours. Cells infected with this virus express:
TVA800; HcRED; and the blasticidin S deaminase (BSD) gene.
Infected cells were selected for two weeks in the presence of 3 mg/
ml blasticidin (Invitrogen, Carlsbad, CA). Cells expressing either
PAPSS1, PAPSS2 or the control cDNA, ZNF639, were generated
by infecting CHO-K1 and IM2 cells with VSV-G pseudotyped
HIV-1 vectors encoding the appropriate ORF (see above) at an
approximate moi of 0.5 blasticidin transducing units for 2 hours.
Infected cells were selected for two weeks in 3 mg/ml blasticidin.
MLV VSV-G and EnvA pseudotyped viruses were generated by
calcium phosphate transfection of 293T cells as previously
described [35,39,40]. VSV-G pseudotyped HIV-1 vector was
produced by a similar proceedure except the genome plasmid used
was pNL4-3.Luc.R-E-. The VSV-G pseudotyped self-inactivating
HIV-1 vector was made using the Virapower kit (Invitrogen,
Carlsbad, CA) following manufacturers instructions. DF-1 cells
were transfected using the calcium phosphate method with the
subgroup A-specific ASLV-A vector, RCASBP (A)-AP, encoding
alkaline phosphatase [37]. Media from transfected cells was
collected 2 days post transfection to 7 days post transfection and
filtered through a 0.45 mm bottle top filter. Virus was stored at
4uC through the collection period, combined and then frozen at
280uC for long-term storage. Virus for use in Quantitative PCR
amplification studies was treated with DNaseI (Roche Applied
Science, Indianapolis, IN) to remove contaminating plasmid DNA
from the virus preps. DNaseI was added as a powder to a final
concentration of 1 mg/ml when the virus containing supernatants
were collected. The supernatants were incubated 1 hr at room
temperature before filtration. The titer of VSV-G and envA vector
stocks were determined by assaying for transduction of a marker
gene following infection of either WT CHO-K1 cells or WT
CHO-K1 cells that had been engineered to express TVA800 [39].
For viruses that lack a cell-based reporter gene assay, immunoblot
analysis of viral capsid protein (CA) levels (a-p24 for HIV or a-p36
for MLV) in the extracellular supernatants of producer cells was
used to equalize the amounts of input virus as compared to those
associated with viral vectors that contain reporter genes (Lenti6/
V5-GW/lacZ[VSV-G] for HIV and MMP-nls-LacZ[VSV-G] for
MLV).
Retroviral Insertional mutagenesis and isolation of an
MLV-resistant clone
CHO-K1 cells (1610
8) were mutagenized by infection with
VSV pseudotyped pRET at an approximate MOI of 0.01 GFP
transducing units. Cells were selected in 900 mg/ml G418 for two
weeks. A pool of 2610
7 insertionally mutagenized CHO-K1 cells
were challenged with CMMP-CD4 [VSV-G] at an approximate
m.o.i of 1 CD4 transducing units for two hours at 37uC 37 in the
presence of 4 mg/ml polybrene. Unbound viruses were then
removed and fresh medium was added. At 48 hours post infection
(hpi) the cells were removed from the plate with phosphate
buffered saline (PBS) containing 5 mM EDTA. Cells were pelleted
(2006g, 5 min) and resuspended in 500 ml PBS containing 2 mM
EDTA and 2% bovine serum albumin (BSA) (Sigma-Aldrich, Inc.,
St. Louis, MO). The cells were incubated with anti-human CD4
iron-conjugated antibody (Miltenyi Biotec Inc., Auburn, CA) at
20 mg/10
7 cells for 15 minutes at 4uC. Large cell (LC) columns
(Miltenyi Biotec Inc., Auburn, CA) were applied to a magnetic
field and washed with 2 ml PBS containing 2 mM EDTA and 2%
BSA. Cells were filtered through a 30 mm mesh (Miltenyi Biotec
Inc., Auburn, CA) and applied to the LC column. Cells were
washed twice with 2 ml PBS containing 2 mM EDTA and 2%
BSA. Column flow through and washes were collected and the
Author Summary
A genetic screen was used to identify host cell functions
important for the replication of retroviruses, including
human immunodeficiency viruses. These studies have
uncovered a heretofore unexpected role for the cellular
sulfonation pathway in an intracellular step of retroviral
replication. Through the addition of sulfate groups, this
pathway is responsible for modifying and regulating
different types of cellular factors including proteins, lipids,
carbohydrates and hormones. The role of this pathway was
further confirmed by using specific chemical inhibitors.
The sulfonation requirement was mapped to a step during
viral DNA integration into the host genome that has a
subsequent effect upon the level of expression of viral
genes. These studies have uncovered a new regulatory
mechanism of retroviral replication and suggest that
components of the host cell sulfonation pathway might
represent attractive targets for antiviral development.
Sulfonation Regulates Retroviral Infection
PLoS Pathogens | www.plospathogens.org 2 November 2008 | Volume 4 | Issue 11 | e1000207cells were pelleted, resuspended in medium and replated. Cells
were allowed to recover for at least 16 hours before the next viral
challenge. When necessary, the cells were expanded between each
round of virus challenge to a minimum of 5610
5 cells per sort.
The challenge and selections were repeated five times. The
population was challenged a final time with CMMP-
HcRED[VSV-G] and the HcRed negative cells were single cell
cloned after high speed FACS (University of Wisconsin Compre-
hensive Cancer Center).
Single cell clones from the sorted insertional mutant pools were
grown for 14 days post sorting, trypsinized and then plated onto
duplicate assay plates. The assay plates were incubated for 2 hours
with pMMP-nls-LacZ [VSV-G] at an approximate m.o.i. of 1
LacZ transducing unit (LTU) in the presence of 4 mg/ml
polybrene. Unbound virus was then removed and fresh medium
was added. At 48 hpi, one plate was assayed for b-galactosidase
activity using the Galacto-Star chemiluminescent kit (Applied
Biosystems, Foster City, CA) according to the manufacturers
instructions and the other plate was assayed for cell number and
cell viability using CellTiter-Glo reagent (Promega, Madison, WI)
following the manufacturers instructions to control for variations
in cell number among the clones.
Chemiluminescent assay of viral infection
Quantitative chemiluminescent infection assays were performed
as previously described [39], briefly, 8 wells of a 96 well plate were
seeded at 1610
4 cells/well for each cell line tested. The cells were
incubated for 2 hours with an approximate m.o.i of 1 transducing
unit (based on marker gene expression for b-galactosidase and
alkaline phosphatase, or CA equivalents for luciferase, as described
above),inthepresenceof4 mg/mlpolybrene.Unboundvirionswere
removed and fresh medium was added. At 48 hpi, four wells were
assayed for b-galactosidase activity using the Galacto-star Kit
(Applied Biosystems, Foster City, CA), for alkaline phosphatase
activity using the Phospha-Light Kit (Applied Biosystems, Foster
City, CA) or for luciferase activity using the Britelite (PerkinElmer,
Boston,MA)according to the manufacturer’sinstructions.Theother
four wells were assayed for cell number and cell viability using
CellTiter-Glo reagent (Promega, Madison, WI) as described above.
The results obtained were normalized for relative cell number.
To determine the absolute fold-resistance to viral infection, X-
Gal staining was performed on cells that were infected with serial
dilutions of viruses. For these experiments, cells were seeded at
1610
4 cells/well in triplicate rows for each cell line tested. The
cells were then infected for 2 hours with ten-fold serial dilutions of
MMP-nls-LacZ [VSV-G] in the presence of 4 mg/ml polybrene as
described before and the cells were subsequently stained with X-
gal as previously described [41]. The blue cells contained in wells
that had between 20 and 200 b-galactosidase positive cells were
counted to give an accurate measure of the viral titer.
PAPS assays
PAPS assays were performed as previously described [42].
Briefly, cells were lysed by three freeze thaw cycles in PAPS lysis
buffer [20 mM Tris pH 8, 20% sucrose, 1 mM EDTA, 1 mM
DTT] in the presence of 16protease inhibitor cocktail (RPI, Mt.
Prospect, IL). Cell lysate (1 ml) was mixed with 5 mM ATP and 10
mCi
[35]S labeled sulfate in reaction buffer [50 mM Tris pH 8,
25 mM MgCl2, 0.9 M EDTA, 13.5 mM DTT) and incubated for
30 minutes at room temperature. Thin layer chromatography
(TLC) was used to separate PAPS, APS and SO4 on PEI cellulose
TLC plate (EMD Chemicals, Gibbstown, NJ) in 0.9 M LiCl. TLC
plates were dried, exposed to phosphoimager plates, and
quantified using the Imagequant software volume method.
Mobility positions were confirmed with commercial PAPS
preparations (PerkinElmer, Waltham MA, Cat# NE-
G010100UC). Each sample was normalized for mg of total protein
in the lysate determined by Bradford assay using the Quick Start
Bradford Dye reagent (Bio-rad, Hercules, CA).
Real time quantitative PCR
To measure the amounts of reverse transcription intermediates
in infected cells, cells were seeded in triplicate wells at 5610
5/well
in a 6 well plate and then infected at 4uC on a rocking platform at
an m.o.i. of 1 GFP transducing unit (GTU) for 2 hours with an
MLV vector (pLEGFP; Clontech, Palo Alto, CA) pseudotyped
with VSV-G that was treated with DNaseI as described above.
Virus derived from pLEGFP was used for these assays because the
39 viral LTR varied enough from pCMMP so realtime PCR
primers could be designed that specifically recognized the
pLEGFP derived test virus but not the pCMMP derived screen
virus. DNA was harvested from infected cells 24 hpi (hpi) using the
DNeasy Kit (Qiagen, Valencia, CA). For the nuclear fractionation
studies nuclei were harvested from infected cells 24 hpi using the
Nuclei EZ Prep Kit (Sigma-Aldrich, Inc., St. Louis, MO) following
the manufacturers instructions and DNA was isolated from nuclei
as described above. To measure integrated proviral DNA copy
number, cells were seeded and infected as described above and
then passaged for 18 days. DNA was then harvested from
1610
6 cells as described above. DNA concentration was calculated
by measuring the A260 on a SPECTRAmax Plus 96 well UV
spectrophotometer (Molecular Devices, Sunnyvale, CA). Quantita-
tive, real time PCR (QPCR) analysis was performed on an ABI 9600
(Applied Biosystems, Foster City, CA) using the standard cycling
conditions of 50uC1 0m i n ,4 0c y c l e so f9 5 uC3 0s ,6 0 uC2m i n u t e s .
DNA (10 ml/25 ml reaction) was amplified in TaqMan Universal
PCR Mastermix (Applied Biosystems, Foster City, CA) with 1 mM
each primer and 0.1 mM5 9,6 - F A M ,3 9TAMRA labeled probe.
Eachprimer probe set was tested oneachcellline ina minimum of 3
independentexperiments.Thenumberofmoleculesineachreaction
was determined by comparison to standard curves generated from
amplification of plasmid DNA containing the target sequence. The
primers used are specific for the U3-U5 region of the LEGFP vector
and are shown along with the viral LTR feature and the bp position
recognized in pLEGFP are: OJWB39 (59-CAGTTCGCTTCTCG-
CTTCTGTTC-39) [U3, bp 523–535], OJWB47 (59-GTCGTGG-
GTAGTCAATCACTCAG-39) [R and U5, bp 697–719] and
OJWB38 (59-6-FAM- ATCCGAATCGTGGTCTCGCTGTTC-
TAMRA-39) [R, bp 657–680].
RNase Protection Assays
Templates for RNA probes to MLV were generated by PCR
amplification using 1 mg total DNA from CHO-K1 cells infected
with CMMP-GFP[VSV-G] along with the oligonucleotide primers
OJWB7 (59-GAACAGATGGTCCCCAGATGC-39) and OJWB8
(59-CGGTGGAACCTCCAAATGAA-39). ExTaq polymerase
(Takara, Madison WI) was used with cycling conditions of
[95uC 5 min, 30 cycles of 95uC3 0S ,5 0 uC3 0S7 2 uC 1 min].
This resulting LTR fragment was cloned into pGem T-easy
(Promega, Madison, WI) and spanned 192 bp upstream of the
transcription start (+1, the start of R) to 139 bp downstream of +1,
which results in a 140 bp protected fragment in the RNase
protection assays. The template for RNA probes to hamster actin
RNA were generated by reverse transcription of the hamster b-
actin cDNA cloned by reverse transcription PCR amplification of
1 mg total RNA isolated from CHO-K1 cells with OJWB313 (59-
TCACCCACACTGTGCCCATCTATGA-39) and OJWB314
(59-CAACGGAACCGCTCATTGCCAATGG-39) and Master-
Sulfonation Regulates Retroviral Infection
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conditions of [60uC 5 min, 30 cycles of 95uC3 0S ,5 0 uC3 0S
72uC 1 min]. The resulting PCR amplified product was cloned
into pGem T-easy (Promega, Madison, WI) and generates a
294 bp protected fragment in RNase protection assays. Anti-sense
RNA probes were generated by digesting the plasmids with SpeI
and performing performing in vitro transcription reaction using
the Riboscribe Kit (Epicenter, Madison WI) with T7 polymerase
and 50 mCi a2
[32]P-UTP.
To measure the amounts of transcription from integrated
proviruses in infected cells, cells were seeded in triplicate wells at
5610
5/well in a 6 well plate and then infected at 4uC on a rocking
platform at an m.o.i. of 1 GTU for 2 hours with an MLV vector
(pCMMP-GFP) pseudotyped with VSV-G. RNA was isolated
form cells 24 hpi using the RNeasy kit (Qiagen, Valencia, CA)
following manufacturers instructions. RNase protection assays
were performed by mixing 2 mg (viral transcripts) or 0.5 mg( b-
actin) of total RNA with 5610
4 cpm probe, hybridizations and
digestions were done using the RPA III kit (Ambion, Ausin TX).
Protected fragments were separated on a 6% PAGE-Urea gel,
dried and exposed to a phosphoimager plate. Phosphorimage units
were measured using the Imagequant software volume method.
Results
Isolation of the IM2 cell line resistant to infection by a
MLV vector
Chinese hamster ovary (CHO-K1) cells were used for insertional
mutagenesis by a retroviral vector since these cells are functionally
hypodiploid at numerous loci [43] and therefore insertion of the
viral vector into a single allele of a given cellular gene can be
sufficient to produce a genetically-null phenotype. The insertional
mutagenesis was performed with the murine leukemia virus (MLV)-
based vector pRET,whichencodesgreen fluorescent protein (GFP),
as well as a neomycin phosphotransferase (NPT) mRNA that
contains an instability element downstream of a canonical splice
donor site [44]. Integration of pRET upstream of a cellular exon
gives rise to a NPT mRNA transcript in which the instability
element is removed by mRNA splicing, thereby conferring G418
resistance on the mutagenized cells (Figure S1A).
Approximately 1610
6 colonies of G418-resistant cells were
generated by challenging CHO-K1 (1610
8) cells with VSV-G
pseudotyped pRET at an moi of 0.01 (note: at this moi only a
small fraction of these cells are ‘‘infected’’) to ensure only one
integration event per cell. Mutagenized cells were selected in
medium containing 900 mg/ml G418 for two weeks, after which
the population was expanded and pooled. In order to identify cells
in the population that were resistant to retroviral infection, a pool
of 2610
7 insertionally mutagenized cells were subjected to five
rounds of challenge with a second, replication-defective, VSV-G
pseudotyped MLV vector which contains a human CD4 gene that
is expressed from the viral promoter (Fig. 1). Infected cells that
expressed human CD4 on their surface were removed from the
population at each round by magnetic cell sorting (MACS) using
an iron-conjugated CD4-specific antibody (Fig. 1). Each round of
infection and sorting resulted in an approximate 3-fold enrichment
of CD4-negative cells relative to the preceding round, with a total
enrichment of 47-fold. The resultant cell population, which
exhibited an overall 2.5-fold resistance to MLV infection, was
then challenged a final time with another VSV-G pseudotyped
MLV vector encoding the far-red fluorescent protein HcRed. A
total of 264 single cell clones of HcRed-negative cells were then
isolated by FACS (Fig. 1) and tested for their susceptibility to
infection by a VSV-G pseudotyped MLV vector encoding b-
galactosidase. One cell line, designated IM2, that was judged to be
one of the most resistant (approximately 12-fold) to challenge by
that viral vector, based upon viral reporter gene expression
(Fig. 2A), is characterized in detail in this report.
To determine if the defect associated with the IM2 cell line is
specific for the MLV vector, wild-type CHO-K1 cells and mutant
IM2 cells were engineered to express TVA800, the cellular
receptor for an avian retrovirus, subgroup A avian sarcoma and
leukosis viruses (ASLV-A) [45,46]. The TVA800 expressing cells
were then challenged with either the MLV vector encoding b-
Figure 1. Scheme used to isolate pRET-mutagenized CHO-K1
cell lines that are resistant to subsequent retroviral infection.
CHO-K1 cells were mutagenized by infection with a VSV-G pseudotyped
pRET vector at a moi of 0.01 G418
R transducing units and selected in
G418 for 2 weeks. Pools of mutagenized cells (1610
7) were challenged
with a VSV-G pseudotyped MLV vector that encodes CD4. Infected cells
were depleted from the population by magnetic sorting with an iron
conjugated anti-CD4 antibody. After five rounds of challenge and
sorting, the enriched pools were infected with a VSV-G pseudotyped
MLV vector that encodes the red fluorescent protein HcRed. The non-
fluorescent cells were single cell cloned by FACS, expanded and seeded
into duplicate assay plates. The assay plates were infected with another
VSV-G pseudotyped MLV vector that encodes b-galactosidase. One plate
was then assayed with a chemiluminescent assay for b-galactosidase.
For controlpurposes,theotherplatewas assayedwithaluciferasebased
chemiluminescent assay to measure viable cell number.
doi:10.1371/journal.ppat.1000207.g001
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protein (EnvA) or instead with an ASLV-A vector that encodes
heat-stable alkaline phosphatase [37]. Viral reporter gene
expression following infection of IM2-TVA800 cells by the
EnvA-pseudotyped MLV vector was 9.7-fold reduced as com-
pared with CHO-K1-TVA800 cells (Fig. 2B). This effect mirrored
that seen with VSV-G pseudotyped MLV vectors (e.g. Fig. 2A).
Thus, the defect seen with IM2 cells is independent of the nature
of the viral glycoprotein used to pseudotype the MLV vector. By
contrast, the level of viral reporter gene expression following
infection by the ASLV-A vector was comparable between IM2-
TVA800 and CHO-K1 cells (Fig. 2B). Since both vectors utilized
EnvA to mediate entry, these observations indicate that the defect
associated with the IM2 cell line is specific for protein or RNA
components of the MLV core.
The PAPSS1 gene is disrupted in IM2 cells
To identify which cellular gene was disrupted by the mutagenic
pRET vector, total RNA was isolated from IM2 cells and reverse
transcription PCR amplification was performed using primers
anchored on the virally encoded NPT gene and the poly (A) tail.
DNA sequence analysis of the PCR amplification products and a
comparison with the sequenced mouse genome revealed that the
pRET provirus had integrated upstream of exon 12 of the 59
phospho-adenosine, 39phosphosulfate synthase 1 gene (PAPSS1)
(Fig. 3A). The full sequence of hamster PAPSS1 gene, and its
corresponding mRNA product, have not yet been reported.
However, comparison with the cognate mouse gene indicates that,
in IM2 cells, the pRET-encoded NPT open reading frame is fused
by mRNA splicing to the third base of the codon encoding amino
acid residue 579 of PAPSS1 (Fig. 3A).
PAPSS1 and the highly related PAPSS2 enzyme catalyze the
formation of the high energy sulfate donor 39 phospho-adenosine,
59phosphosulfate (PAPS) [42,47,48] used for all sulfonation
reactions in the cell. Consistent with the prediction that IM2 cells
have less PAPS available for sulfonation reactions, IM2 cells
incorporated 17% less
[35]SO4 into macromolecules than CHO-
K1 cells in bulk labeling experiments (Figure S2). However, the
readout of these experiments is several steps downstream of PAPS
synthase and represents the summation of multiple enzyme/
substrate interactions. To directly determine if IM2 cells were
deficient in PAPS synthase activity, an in vitro PAPS assay was
performed. ATP and
[35]SO4 were mixed with cell lysates
prepared from CHO-K1 cells, IM2 cells, or IM2 cells engineered
to express human cDNA clones of either PAPSS1 or PAPSS2. The
reaction products were separated on PEI cellulose TLC plates in
0.9 M LiCl. (Fig. 3B) Inorganic sulfate exhibits the greatest
mobility, followed by the reaction intermediate adenosine
phosphosulfate (APS), with PAPS being retained closest to the
origin [47]. Mobility positions were confirmed with commercial
PAPS preparations (data not shown). TLC plates were exposed to
phosphoimager plates and the levels of PAPS synthesized were
measured. These studies demonstrated that IM2 cells have five-
fold lower levels of PAPSS activity per mg of protein than do the
parental CHO-K1 cells (Fig. 3B and 3C). PAPS synthase activity
in IM2 cells was significantly increased by stable expression of
either human PAPSS1 or PAPSS2 cDNA clones (Fig. 3B and 3C)
although not to full WT levels. These data indicate that the pRET
vector disrupted the function of the PAPSS1 gene in IM2 cells.
The cellular sulfonation pathway is required for MLV
infection
To investigate whether the deficiency in PAPS synthase activity
in IM2 cells was responsible for the block to MLV infection,
Figure 2. Resistance of the IM2 cell line maps to the MLV core.
(A) CHO-K1and IM2 cells were challenged with serial dilutions of the
VSV-G pseudotyped MLV vector (MMP-nls-lacZ[VSV-G]), encoding b-
galactosidase. The cells were then stained 48 hpi with X-gal, the
number of blue cells were counted, and the data reported as the
percentage of LacZ transducing units (LTU) obtained from WT CHO-K1
infections (5610
5 LTU). The data shown are the average of three
experiments each performed with triplicate samples. Error bars indicate
the standard deviation of the data. (B) CHO-K1 cells and IM2 cells,
engineered to express TVA800, or wild-type CHO-K1 cells, were
challenged with either pMMp-nls-LacZ[envA], an EnvA pseudotyped
MLV vector encoding b-galactosidase, or with RCASBP(A)-AP, an ALSV-A
vector encoding heat stable alkaline phosphatase. Infection was
monitored using chemiluminescent assays to detect reporter enzyme
activities along with a chemiluminescent assay to measure relative
viable cell numbers. The ratios of [enzyme activities:relative viable cell
number] were calculated for each sample and compared with values
from CHO-K1 TVA 800 cells (defined as 100% infection). The data shown
are the average mean values obtained in an experiment performed with
quadruplicate samples and are representative of three independent
experiments. Error bars indicate the standard deviation of the data.
doi:10.1371/journal.ppat.1000207.g002
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PLoS Pathogens | www.plospathogens.org 5 November 2008 | Volume 4 | Issue 11 | e1000207CHO-K1 and IM2 cells engineered to express either human
PAPSS1 or PAPSS2 were challenged with the VSV-G pseudo-
typed MLV vector encoding b-galactosidase and infected cells
were enumerated by X-gal staining. Expression of either PAPSS
enzyme complemented the MLV infection defect of the IM2 cell
line (Fig. 4A). By contrast, a control cDNA, containing an ORF
unrelated to sulfonation, did not rescue virus infectivity in these
cells (Fig. 4A). These data confirm that the deficiency in PAPS
synthase activity is responsible for the virus infection-resistant
phenotype of IM2 cells.
To further investigate a role for the sulfonation pathway, CHO-
K1 cells were treated with either chlorate, a substrate analog of
sulfate and a competitive inhibitor of PAPS synthases [48–51], or
with the sulfotransferase inhibitor guaiacol [50,51], prior to
challenge with the MLV vector. As compared to untreated cells,
chlorate-treated, guiacol-treated, and chlorate/guaiacol dual-
treated cells gave rise to approximately 6.7-fold, 3.4-fold, and
23-fold less blue cells, respectively (Fig. 4B). Only the dual
inhibitor treatment led to a significant (2.3-fold) reduction in viable
cell number (Fig. 4C), which was still considerably less than the
effect on infection. Similarly, chicken DF1 cells treated with
chlorate were approximately 9.3-fold less susceptible to infection
by this viral vector as judged by reporter gene expression (Fig. 4D).
However, this treatment did not influence infection of these avian
cells by an ASLV-A vector. Treatment of IM2 cells with chlorate
reduced MLV infection an additional 2-fold (Figure S3), which is
consistent with the observation that these cells contain some
residual PAPS synthase activity (Fig. 3B and 3C). These data
Figure 3. PAPS synthase 1 gene is disrupted in IM2 cells. (A) The pRET mutagenic vector is integrated upstream of exon 12 of the PAPSS1
gene. The nucleotide sequence of the fusion junction that is formed via mRNA splicing involving the splice donor located downstream of the NPT
gene in pRET, and the splice acceptor located upstream of exon 12 of the hamster PAPSS1 gene is shown. Since the hamster PAPSS1 gene has not
been previously characterized by DNA sequencing, this sequence at the fusion junction is shown aligned with that of the corresponding mouse
PAPSS1 exon 11-exon 12 junction nucleotide sequence. The amino acid sequence encoded by this region of mouse PAPSS1 is also shown. The
nucleotide differences between the hamster and mouse sequences occur at codon wobble positions (indicated with lowercase letters) that do not
alter the amino acid sequence. (B) IM2 cells were engineered to express human PAPSS1 or PAPSS2, or a control cDNA, as described under Materials
and Methods. Lysates prepared from these cells were assayed for PAPSS activity by adding ATP and
[35]S labeled sulfate, and the samples were then
subjected to thin layer chromatography to separate the substrate from the reaction products (APS and PAPS). The experiment shown is
representative of three independent experiments. (C) The amounts of PAPS synthesized in the samples shown in panel C were quantitated as
described under Materials and Methods and are shown relative to the amount produced by the wild-type CHO-K1 cell extract (defined as 100%). The
data shown are the average of three independent experiments. Error bars indicate the standard deviation of the data.
doi:10.1371/journal.ppat.1000207.g003
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PLoS Pathogens | www.plospathogens.org 6 November 2008 | Volume 4 | Issue 11 | e1000207Figure 4. PAPSS activity is required for efficient MLV infection. (A) CHO-K1and IM2 cells engeneered to express either a control cDNA,
human PAPSS1 or human PAPSS2 were challenged with serial dilutions of the VSV-G pseudotyped MLV vector (MMP-nls-lacZ[VSV-G]), encoding b-
galactosidase. The cells were then stained 48 hpi with X-gal, the number of blue cells were counted, and the data reported as the percentage of LacZ
transducing units (LTU) obtained from WT CHO-K1 infections (5610
5 LTU). The data shown are the average mean values obtained with triplicate
samples. (B and C) CHO-K1 cells were challenged with a VSV-G pseudotyped MLV vector MMP-nls-lacZ[VSV-G]) in the presence of either 100 mM
chlorate, 5 mM Guaiacol, or both 100 mM chlorate and 5 mM Guaiacol. The cells were subsequently assayed for either b-galactosidase activity using
a chemiluminescent assay (B), or for viable cell number using a chemiluminescent assay (C). The data in panels B and C are the average mean values
obtained in an experiment performed with quadruplicate samples and are reported as a percentage of that seen with untreated cells. (D) Chicken DF-
1 cells were challenged with either the MLV vector pMMp-nls-LacZ[VSV-G], or the ASLV-A vector RCASBP(A)-AP in the presence of 100 mM chlorate
and assayed 48 hpi with chemiluminescent assays for reporter enzyme activities or viable cell number. The ratios of [enzyme activities:relative viable
cell number] were calculated for each sample and compared with untreated controls (defined as 100% infection). The data shown are the average
mean values obtained in an experiment performed with quadruplicate samples. The results shown in panels A–D are representative of three
independent experiments and error bars indicate the standard deviation of the data.
doi:10.1371/journal.ppat.1000207.g004
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by MLV, but not ASLV, vectors and indicate that the
mechanism(s) responsible are shared between different host cell
species.
The sulfonation pathway does not influence viral reverse
transcription, or the level of proviral DNA
Real time PCR amplification was used to monitor the effect of
the sulfonation pathway on the levels of reverse transcription
products and integrated viral DNA. Cells were infected with an
MLV vector (pLEGFP) and either total DNA or nuclear DNA was
subsequently harvested. Since these cells potentially contain both
the mutagenic pRET vector, and the pCMMP derived vector
utilized in the screen, the primer/probe set was chosen to amplify
the plus strand strong stop replication intermediate [52,53] and
annealed specifically to the unique 3 (U3) and unique 5 (U5) long
terminal repeat (LTR) region of only the pLEGFP MLV vector
(data not shown). This primer probe set exhibits an excellent dose
response over 6 orders of magnitude (Figure S4A) and a very low
background, such that the signal from infected cells at 24 hpi is
400-fold higher than from cells where the virus is bound but not
internalized (0 hpi, Fig. 5A) The difference between infected and
uninfected cells is even greater (Fig. 5D and Figure S4B). The
levels of total and nuclear reverse transcription products were
found to be the same in IM2 cells as in CHO-K1 cells (Fig. 5A and
5B). Furthermore, treatment of CHO-K1 cells with chlorate had
no effect on the accumulation of viral reverse transcription
products, confirming that the sulfonation pathway does not
influence viral DNA synthesis (Fig. 5C). Importantly, this is not
due to saturation of the assay as dilution of input genomic DNA
showed a proportionate decrease in both CHO-K1 and IM2
samples, even when a ten-fold higher multiplicity of infection was
used (Figure S4B). To investigate the possible role of this pathway
in viral DNA integration, IM2 cells were infected with the same
MLV vector, passaged for 18 days to allow loss of episomal forms
of viral DNA [54,55], and the levels of total viral DNA were then
measured. IM2 cells and chlorate treated CHO-K1 cells contained
nearly the same amounts of integrated viral DNA as untreated
CHO-K1 cells (1.1 and 2.6-fold less, respectively) (Fig. 5D), which
is insufficient to explain the approximately 10-fold decrease in
infectivity (Fig. 2A and 4B). By comparison at 18 days post-
infection, nearly 400-fold lower levels of viral vector DNA were
detected in MCL7 cells, a chemically mutagenized CHO-K1 cell
line that exhibits a strong block to MLV DNA integration [39]
(Fig. 5D). These data demonstrate that the cellular sulfonation
pathway does not influence either the levels of viral DNA that are
synthesized in the target cell or that become integrated into the
host cell genome.
The sulfonation pathway influences gene expression
from the MLV LTR
Since the sulfonation pathway did not influence the level of
integrated viral DNA, we next determined if it impacts subsequent
provirus gene expression. In these studies, the level of MLV LTR-
driven transcription from the MMP-nls-LacZ vector was compared
to that from the internal CMV promoter contained in QCLIN, a
commercially available, self-inactivating (SIN) MLV vector with
promoter defective LTRs [56]. The levels of b-galalactosidase from
the QCLIN vector were the same in infected IM2 and CHO-K1
cells (Fig. 6A), a result that supports our observation that the
sulfonation pathway doesnot influence theoveralllevel of viral DNA
integration. By striking contrast, MLV LTR-driven reporter gene
expression following infection was reduced 5.6-fold in IM2 cells as
compared with CHO-K1 cells(Fig.6A). Consistently,a combination
of chlorate and guaiacol treatment reduced b-galalactosidase levels
produced from the MMP-nls-lacZ vector by 7.3-fold, following
infection of CHO-K1 cells, but this treatment did not influence gene
expression from the SIN vector (Fig. 6B). These data suggest that the
target of action for the cellular sulfonation pathway is contained
within the MLV LTR.
To directly examine the influence of the sulfonation pathway
upon MLV LTR-driven mRNA transcription, total RNA was
isolated from CHO-K1 and IM2 cells that were infected with a
VSV G-pseudotyped MLV vector encoding EGFP. RNase
protection assays were performed with a probe that hybridizes
to the primary viral mRNA transcript (hybridizing to the R-U5
region). IM2 cells accumulated 3.5-fold less primary transcript
than CHO-K1 cells (Fig. 6C & E). Similarly, the levels of viral-
derived transcript were reduced in CHO-K1 cells treated with
inhibitors of the cellular sulfonation pathway (Chlorate 11- fold,
guaiacol 17- fold, and chlorate and guaiacol 40- fold (Fig. 6D & E).
All values were normalized to hamster b-actin levels, which varied
less than 2-fold in all cases (Fig. 6C and 6D). These data indicate
that the sulfonation pathway influences a step that impacts the
transcriptional competency of the provirus.
The sulfonation pathway acts at a step during provirus
establishment
To determine the time point during infection when the cellular
sulfonation pathway is involved, CHO-K1 cells were incubated with
the VSV-G pseudotyped MLV vector encoding b-galactosidase at
4uC, and infection was then initiated by a temperature shift to 37uC.
Chlorate was then added at various times post-infection and the
effect of this treatment on the establishment of viral vector in these
cells was then measured by quantitating b-galalactosidase expres-
sion. Chlorate addition up to 16 hpi led to a reduction in subsequent
viral reporter gene expression (Fig. 7A). However, addition of the
inhibitor at time points 18 hpi, or later, had no effect (Fig. 7A). This
timing coincides with maximal levels of viral DNA integration [57],
suggesting that the cellular sulfonation pathway might influence a
step during or shortly after provirus establishment.
To explore this possibility further we compared the effect of
chorate treatment on proviral gene expression from resident,
versus newly acquired, proviruses. A CHO-K1 cell line was
established that contains a resident MLV vector encoding secreted
alkaline phosphatase (Fig. 7B). These cells were then challenged
with the MLV vector encoding b-galactosidase in the presence of
chlorate to generate newly acquired MLV proviruses under
conditions where the sulfonation pathway was inhibited. These
experiments showed that the chlorate treatment affected gene
expression from the newly acquired, but not the resident
proviruses (Fig. 7B). In an independent experiment, chlorate
treatment was shown not to influence b-galalactosidase expression
from a resident MLV vector (data not shown), confirming that the
effect seen was not reporter gene-specific. Taken together with the
timing of the sulfonation requirement during infection (Fig. 7A),
these results strongly imply that this cellular pathway influences
MLV replication at a step during provirus establishment, one that
impacts subsequent viral gene expression.
The sulfonation pathway affects HIV LTR-driven
transcription
The previous experiments showed that the sulfonation pathway
affects LTR-driven gene expression from newly acquired MLV,
but not ASLV, proviruses. To test the influence of this pathway on
HIV-1 LTR-driven gene expression, CHO-K1 and IM2 cells were
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PLoS Pathogens | www.plospathogens.org 8 November 2008 | Volume 4 | Issue 11 | e1000207Figure 5. The sulfonation pathway does not influence reverse transcription or the level of integrated virus DNA. (A and B) CHO-K1 cell
lines were challenged with the VSV-G pseudotyped MLV vector LEGFP. Total DNA (A) or DNA from isolated nuclei (B) were harvested at 0 or 24 hpi,
DNA concentration was quantitated by A260, and a real-time PCR amplification analysis was performed to measure the levels of viral DNA that were
synthesized. (C) Untreated CHO-K1 cells or CHO-K1 cells that had been pretreated for 16 hrs with 100 mM chlorate and maintained in medium
containing this concentration of chlorate were challenged with the MLV vector and subsequently analyzed for reverse transcription products as
described in panel A. (D) CHO-K1 cells that were either untreated or treated with 100 mM chlorate, IM2 cells, and MCL7 cells, were challenged with
the same VSV-G pseudotyped MLV vector and total DNA was harvested at 1 or 18 days post infection for real time PCR quantitation of viral DNA
products. The chemically-mutagenized MCL7 cell line displays a strong block to MLV DNA integration [39]. Chlorate treated CHO-K1 cells were
passaged in medium containing 100 mM chlorate for the duration of the experiment. The data shown in panels A–D are the average mean values
obtained in independent experiments performed with triplicate samples and each is representative of three independent experiments. Error bars
indicate the standard deviation of the data.
doi:10.1371/journal.ppat.1000207.g005
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PLoS Pathogens | www.plospathogens.org 9 November 2008 | Volume 4 | Issue 11 | e1000207Figure 6. The sulfonation pathway influences transcription specifically from the MLV LTR. (A) CHO-K1 or IM2 cells were challenged with
the VSV-G pseudotyped MLV vectors MMP-nls-lacZ, which directs MLV LTR-driven lacZ gene expression, or with pQCLIN, a self-inactivating MLV
vector with defective LTRs and an internal CMV promoter which drives lacZ expression. The cells were subsequently assayed for b-galactosidase
activity and viable cell number and the data reported as in Fig. 2B with the ratio of [b-galactosidase activity: relative viable cell number] observed
with CHO-K1 cells defined as 100% infection. (B) CHO-K1cells were challenged with the same virus vectors used in panel A but in the presence of
100 mM chlorate and 5 mM Guaiacol. The cells were subsequently assayed for b-galactosidase activity as in panel A. The data shown in panels A and
B are the average mean values obtained in an experiment performed with quadruplicate samples and each is representative of three independent
experiments. (C) Total RNA was isolated from CHO-K1 or IM2 cells that had been infected with the VSV-G pseudotyped MLV vector pCMMP- EGFP.
RNase protection assays were performed using a probe that recognizes either the provirus-derived transcript or the hamster b-actin gene. Protected
fragments were separated, subjected to gel electrophoresis as described under Materials and Methods, and exposed to a phosphoimager plate. (D)
CHO-K1 cells were challenged with virus as in panel C in the presence of either 100 mM chlorate, 5 mM guaiacol, or with both inhibitors. The
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one with luciferase expressed from the viral LTR and the other a
SIN vector with b-galactosidase expressed from an internal CMV
promoter. Reporter gene expression from the HIV-LTR was
reduced 5-fold in IM2 versus CHO-K1 cells whereas that from the
internal CMV promoter was the same in both cell types (Fig. 8A).
Consistently, treatment of CHO-K1 cells with chlorate, guaiacol,
or with both inhibitors resulted in 10-, 8-, and 12-fold reductions
in HIV LTR-driven reporter gene expression, respectively. By
contrast, internal CMV promoter-driven reporter gene expression
was unaltered or was slightly enhanced by these treatments
(Fig. 8B). Similar results were observed using human Jurkat T cells
infected with VSV-G pseudotyped HIV or MLV viral vectors that
express luciferase from the viral LTRs (Fig. 8C). Therefore as for
MLV, HIV LTR-driven gene expression is also regulated by the
cellular sulfonation pathway.
Discussion
Here we have presented multiple lines of evidence that the host
cell sulfonation pathway influences retroviral infection by affecting a
step during provirus establishment, one that modulates gene
expression from the viral LTR promoter. First, insertional
mutagenesis and genetic complementation studies identified
PAPSS1 as a cellular gene that is important for MLV infection.
Second, a similar defect was seen with cells treated with the PAPS
synthetase inhibitor, chlorate, or with the sulfotransferase inhibitor,
guaiacol.Third, inhibition ofthe sulfonation pathwayhad noimpact
on the levels of integrated MLV DNA but influenced downstream
MLV LTR-driven gene expression from newly formed proviruses.
Fourth, MLV was sensitive to inhibitors of the sulfonation pathway
at time points up to that associated with maximal levelsof viral DNA
integration [57]. Finally, the observations made with MLV held true
for HIV-1, the causative agent of AIDS, since the sulfonation
pathway also influenced LTR-driven transcription from that virus.
These data suggest that sulfonation may play an important role in
the regulation of nuclear gene expression. Consistent with this,
PAPSS1 localizes to the nucleus, which implies there is a
requirement for high levels of PAPS, and by extension sulfonation,
in the nucleus [58]. Thus, these studies have uncovered a heretofore
unknown regulatory step of retroviral replication, one that is
potentially important for HIV/AIDS therapy.
The data in this report are consistent with either one of two
models. In the first model, the sulfonation pathway might influence
viral DNA integration site specificity so that when this pathway is
impaired, the virus is targeted to regions where the provirus is less
transcriptionally competent. This model is consistent with the
observation that viruses sensitive to the sulfonation pathway, HIV
and MLV, both share a strong preference for integration into
genes, although MLV shows a much stronger preference for
integration near the viral promoter regions [59–62]. By contrast,
ASLV, which is not influenced by this pathway, shows little or no
preference for integration into genes [60,63].
In the second model, the sulfonation pathway might have no
impact upon integration site specificity but, during integration or
shortly thereafter, the sulfonation pathway might influence the
nature of epigenetic modifications introduced onto the viral DNA.
These modifications could, in turn, regulate the transcriptional
competency of the provirus. Sulfonation induced changes in DNA
methylation, histone acetylation, methylation or positioning are all
potential processes which could affect the transcriptional activity of
the provirus [64,65]. Indeed the importance of epigenetic
modifications in HIV transcription is apparent in a recent large
scale analysis of HIV integration sites which revealed a positive
correlation between integration and epigenetic modifications
favoring transcription and a negative correlation with modifica-
tions that silence transcription [66]. We are currently performing
experiments aimed at distinguishing between these two models.
The host cell sulfonation pathway involves a set of golgi and
cytoplasmic sulfotransferases (SULTs) that transfer the sulfonate
from PAPS to target substrates. In humans there are thirteen distinct
cytosolic SULTs, arranged into three different families, and these
enzymes are involved in the metabolism of steroids, bile acids,
neurotransmitters, and xenobiotics [67]. Golgi sulfotransferases are
involved in sulfonating carbohydrates, generating the glycosamino-
glycans (GAGs), heparan sulfate, chondroitin/dermatan sulfate, and
keratan sulfate [68], as well as glycolipids [29]. Two golgi
tyrosylprotein sulfotransfrerases (TPST-1 and TPST-2) are respon-
sible for sulfonation of tyrosine residues on proteins and peptides.
Tyrosyl sulfonation can have important regulatory effects on cell
surface proteins including an influence on protein-protein interac-
tions [69], as exemplified by the requirement for sulfonation of
tyrosine residues at the amino-terminus of the CCR5 chemokine
receptor for high affinity interaction with both its natural ligands,
MIP-1a and MIP-1b, as well as with HIV-1 gp120 [70]. This entry
effectseenpreviouslyisdistinctfromourobservationthatsulfonation
also affects a post entry step coinciding with provirus establishment.
Since inhibition of sulfonation can block HIV at multiple stages of
the viral lifecycle, the cellular sulfonation pathway is an intriguing
target for the development of novel antivirals.
Future work will be aimed at identifying the specific
components of the sulfonation pathway that are critical for
modulating MLV and HIV-1 infection. We expect that this
information will help to uncover precisely how the sulfonation
pathway regulates retroviral infection at a step coincident with
provirus establishment and that influences the subsequent
transcriptional competency of the provirus.
Supporting Information
Figure S1 Schematic diagrams of the proviral forms of MLV
vectors used in this report. A. Following integration of the pRET
vector in a reverse orientation within an intron of a cellular gene,
mRNA splicing gives rise to an IRES-containing transcript that
encodes GFP. An internal promoter drives expression of the
neomycin phosphotransferase gene (NPT) which confers G418
resistance only when a downstream mRNA instability motif is
removed by splicing to a downstream cellular exon. A downstream
poly (A) signal derived from the cellular gene is captured to
stabilize the RNA. B. The MLV pCMMP based vectors have the
gag/pol and env genes replaced with various reporter genes,
including CD4, HcRed, LacZ, and luciferase. Reporter gene
expression is driven from the viral LTR. The MLV vector
pLEGFP has a similar structure but has both WT LTRs and an
internal CMV promoter driving GFP expression. C. The self-
inactivating MLV vector pQLIN has the U3 elements of the viral
inhibitors were present throughout the infection. (E) The mean average data of at least three independent RNase protection experiments, conducted
as in panels C and D, were quantitated by phosphorimaging using the image quant software volume method. The relative levels of viral transcripts
were normalized to the corresponding b-actin levels and are reported as a percentage of those seen with untreated CHO-K1 cells (defined as 100%).
Error bars in panels A, B and E, indicate the standard deviation of the data.
doi:10.1371/journal.ppat.1000207.g006
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PLoS Pathogens | www.plospathogens.org 11 November 2008 | Volume 4 | Issue 11 | e1000207Figure 7. Chlorate treatment during virus infection reduces reporter gene expression from newly acquired, but not resident
proviruses. (A) CHO-K1 cells (1610
5) were challenged with 5610
5 IU of MMP-nls-lacZ[VSV-G] at 4uC for 2 hrs and then warmed to 37uC to initiate
infection at t=0 mins. Chlorate was added to 100 mM final concentration at the indicated hours post infection (hpi). At 48 hpi, the cells were assayed
for b-galactosidase activity and for relative viable cell numbers and the level of infection was calculated as in Fig. 2B. The data shown are the average
mean values obtained in an experiment performed with triplicate samples. (B) Cells harboring a resident MLV provirus, pCMMP-SEAP, encoding
secreted alkaline phosphatase, were challenged with a second MLV vector, MMP-nls-lacZ[VSV-G] encoding b-galactosidase, in the presence of
100 mM chlorate. Chemiluminescent assays were then used to measure reporter enzyme activity levels (panel B), as well as relative viable cell
numbers (panel C), and the values obtained with untreated cells was defined as 100% in each case. The data shown in panels C and D are the average
mean values obtained in an experiment performed with quadruplicate samples. The data in panels A–C are representative of three independent
experiments and error bars indicate the standard deviation of the data.
doi:10.1371/journal.ppat.1000207.g007
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PLoS Pathogens | www.plospathogens.org 12 November 2008 | Volume 4 | Issue 11 | e1000207Figure 8. PAPSS activity affects transcription from the HIV-1 LTR. (A) CHO-K1 or IM2 cells were challenged with either one of two VSV-G
pseudotyped HIV-1 vectors, NL43E-R-Luc, that directs luciferase gene transcription from the viral LTR, or with pLenti6/V5-GW/LacZ, a self inactivating
HIV-1 vector from which b-galactosidase expression is driven by an internal CMV promoter. Chemiluminescent assays were used to measure reporter
enzyme activities and viable cell numbers. The data shown was calculated as in panel Fig. 2B and the value obtained with CHO-K1 cells was defined
as 100% infection. (B) CHO-K1 cells were challenged with the viruses described in panel A, in the presence of either 100 mM chlorate, 5 mM Guaiacol
or both inhibitors and subsequently assayed as in panel A. (C) Jurkat cells were spin inoculated with the VSV-G pseudotyped vectors NL43E-R-
Luc[VSV-G] or MLV-LUC (an MLV vector that encodes luciferase) in the presence of 120 mM Chlorate, 5 mM guaiacol or both inhibitors.
Chemiluminescent assays were used to monitor virus infection as in panel A. The viable cell number observed in the experiment shown in panel C is
reported in panel D. For panels B–D the data are reported as the percentage of untreated controls. For panels A–D, the data is the average mean
values obtained in an experiment with quadruplicate samples and are representative of three independent experiments. Error bars indicate the
standard deviation of the data.
doi:10.1371/journal.ppat.1000207.g008
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CMV promoter driving expression of the LacZ gene.
Found at: doi:10.1371/journal.ppat.1000207.s001 (0.49 MB TIF)
Figure S2 Total sulfonation of macromolecules is reduced in
IM2 cells. CHO-K1 and IM2 cells were incubated in sulfate free
media supplemented with 200 mCi/ml
[35]SO4 for 48 hours. Cells
were then harvested in 50 mM Tris-pH 7.0, 2% SDS. The
samples were then precipitated in 25% TCA. The precipitates
were washed 36with 5% TCA, once with 95% ethanol and air
dried. Samples were suspended in scintillation fluid and counted
for 1 minute, and incorporation of label was normalized to CHO-
K1 values. Values shown are the average of quadruplicate sample
readings from two independent labeling experiments. Error bars
indicate the standard deviation of the data.
Found at: doi:10.1371/journal.ppat.1000207.s002 (0.11 MB TIF)
Figure S3 Effect of chlorate on MLV vector infection of IM2
cells. IM2 cells were challenged with the MLV vector pMMp-nls-
LacZ[VSV-G] in the presence of 120 mM chlorate and assayed
48 hpi with chemiluminescent assays for reporter enzyme activities
or viable cell number. The ratios of [enzyme activities:relative
viable cell number] were calculated for each sample and compared
with untreated controls (defined as 100% infection). The data
shown are the average mean values obtained in an experiment
performed with quadruplicate samples. The results are represen-
tative of three independent experiments and error bars indicate
the standard deviation of the data.
Found at: doi:10.1371/journal.ppat.1000207.s003 (0.11 MB TIF)
Figure S4 Standard curve of real-time quantitative PCR
analysis. Serial dilutions of pLEGFP-C1 plasmid were amplified
as described in materials and methods and the threshold cycle
value for each dilution was plotted against the number of input
molecules of DNA. Non-linear regression analysis was performed
on the data and the r
2 value was used to determine the fit of the
data. This data was used to generate the standard curve for
Figure 5D. (B) To determine if the QPCR assay was linear under
the conditions of our analysis, 1610
6 cells were infected at an
m.o.i. of 10 (10 times higher than the amounts used in our
standard assay conditions in Fig. 5), total DNA was isolated and
then real time PCR analysis was performed as described in
materials and methods using the indicated dilutions of input viral
DNA (used as a surrogate marker of the number of virions added).
The data shown are the average mean values obtained in
independent experiments performed with triplicate samples and
each is representative of three independent experiments. Error
bars indicate the standard deviation of the data.
Found at: doi:10.1371/journal.ppat.1000207.s004 (0.39 MB TIF)
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